These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28796997)

  • 21. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
    Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H
    Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
    Fauser S; Muether PS
    Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Effects of Intravitreal Aflibercept and Ranibizumab on Systemic Inflammatory and Cardiovascular Biomarkers in Patients with Neovascular Age-related Macular Degeneration.
    Erdem B; Gok M
    Curr Eye Res; 2021 Sep; 46(9):1387-1392. PubMed ID: 33471564
    [No Abstract]   [Full Text] [Related]  

  • 24. Aqueous Humor Levels of Cytokines in Patients with Age-Related Macular Degeneration.
    Mimura T; Funatsu H; Noma H; Shimura M; Kamei Y; Yoshida M; Kondo A; Watanabe E; Mizota A
    Ophthalmologica; 2019; 241(2):81-89. PubMed ID: 30048978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.
    Singh RP; Srivastava S; Ehlers JP; Bedi R; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i22-27. PubMed ID: 24836866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema.
    Shimura M; Yasuda K; Motohashi R; Kotake O; Noma H
    Br J Ophthalmol; 2017 Nov; 101(11):1518-1523. PubMed ID: 28270488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
    Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
    Front Immunol; 2021; 12():738521. PubMed ID: 34721402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration.
    Fauser S; Schwabecker V; Muether PS
    Am J Ophthalmol; 2014 Sep; 158(3):532-6. PubMed ID: 24879948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Kanadani TCM; Veloso CE; Nehemy MB
    Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
    Mantel I; Dirani A; Zola M; Parvin P; De Massougnes S; Bergin C
    Retina; 2019 May; 39(5):906-917. PubMed ID: 29370035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
    Khurana RN; Rahimy E; Joseph WA; Saroj N; Gibson A; Vitti R; Berliner AJ; Chu K; Cheng Y; Boyer DS
    Am J Ophthalmol; 2019 Apr; 200():161-168. PubMed ID: 30664844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Kakinoki M; Miyake T; Kawamura H; Saishin Y; Liu P; Ohji M
    Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1033-9. PubMed ID: 24196779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema.
    Utsumi T; Noma H; Yasuda K; Goto H; Shimura M
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2597-2603. PubMed ID: 33772356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
    Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
    Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M; Kano M; Itagaki K; Sekiryu T
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.